ASPG and acute myeloid leukemia: Although the exact mechanism is not clear, the results suggest that the combination of ADI‐PEG20 with LDC may delay the development of anti‐ADI‐PEG20 antibodies and prolong the duration of arginine depletion for patients with AML, in a manner similar to cytarabine decreasing antibodies against asparaginase in children with ALL.49